

Factors influencing survival in high-grade gliomas

Seminars in Oncology

30, 10-14

DOI: [10.1053/j.seminoncol.2003.11.031](https://doi.org/10.1053/j.seminoncol.2003.11.031)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Toward a Glioblastoma Vaccine: Promise and Potential Pitfalls. <i>Journal of Clinical Oncology</i> , 2004, 22, 4240-4243.	0.8	11
2	Apurinic Endonuclease Activity in Adult Gliomas and Time to Tumor Progression after Alkylating Agent-Based Chemotherapy and after Radiotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 7875-7883.	3.2	47
3	Current issues in diagnosis and treatment of primary and metastatic brain tumors. <i>Seminars in Oncology</i> , 2004, 31, 593-594.	0.8	2
4	Bromophenol Blue Staining of Tumors in a Rat Glioma Model. <i>Neurosurgery</i> , 2005, 57, 1041-1047.	0.6	35
5	The treatment of malignant gliomas. <i>Current Treatment Options in Neurology</i> , 2005, 7, 293-303.	0.7	15
6	Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. <i>Journal of Neuro-Oncology</i> , 2005, 71, 319-323.	1.4	46
7	The results of postoperative irradiation in malignant glioma patients. <i>Reports of Practical Oncology and Radiotherapy</i> , 2005, 10, 27-35.	0.3	0
8	Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas. <i>Clinical Cancer Research</i> , 2005, 11, 5167-5174.	3.2	181
9	Health-related quality of life and symptom research in glioblastoma multiforme patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 763-774.	0.7	14
10	RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. <i>Rna</i> , 2005, 12, 187-191.	1.6	270
11	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	13.9	17,395
12	Imatinib may be useful in the management of patients with glioblastoma. <i>Medical Hypotheses</i> , 2005, 65, 1205-1206.	0.8	2
13	Glioblastoma multiforme: advances in postsurgical management. <i>Community Oncology</i> , 2006, 3, 678-683.	0.2	4
14	Estratgias auxiliares para graduao dos tumores astrocticos segundo os critrios histopatolgicos estabelecidos pela OMS. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2006, 42, 401.	0.3	0
15	VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME. <i>Neurosurgery</i> , 2006, 59, 1078-1085.	0.6	19
16	Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 788-799.	0.4	23
17	Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: A retrospective study from the Rare Cancer Network. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 179-186.	0.4	59
18	Chemotherapy Resistance. , 2006, , 89-104.		1

#	ARTICLE	IF	CITATIONS
19	Cystemustine in recurrent high grade glioma. Journal of Neuro-Oncology, 2006, 79, 33-37.	1.4	8
20	Advances in the treatment of primary brain tumors: Dawn of a new era?. Current Oncology Reports, 2006, 8, 45-49.	1.8	8
21	Thallium-201 SPECT in prognostic assessment of malignant gliomas treated with postoperative radiotherapy. Annals of Nuclear Medicine, 2006, 20, 287-294.	1.2	10
22	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. Cancer Genetics and Cytogenetics, 2006, 166, 46-55.	1.0	22
23	High-grade glioma: Can we teach an old dogma new tricks?. Cancer Cell, 2006, 9, 147-148.	7.7	5
24	Intra-operative Ultrasound Elastography and Registered Magnetic Resonance Imaging of Brain Tumours: A Feasibility Study. Ultrasound, 2006, 14, 43-49.	0.3	21
25	Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-Oncology, 2006, 8, 253-260.	0.6	67
26	The Methionine Synthase Polymorphism c.2756A>G Alters Susceptibility to Glioblastoma Multiforme. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2314-2316.	1.1	25
27	Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. British Journal of Cancer, 2006, 95, 862-868.	2.9	26
28	Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma. Clinical Cancer Research, 2007, 13, 1253-1259.	3.2	1,005
29	Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma. British Journal of Cancer, 2007, 96, 960-969.	2.9	32
30	Should patients with anaplastic oligodendroglial tumors receive adjuvant chemotherapy?. Nature Clinical Practice Neurology, 2007, 3, 14-15.	2.7	0
31	Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. Journal of Neurosurgery, 2007, 106, 601-608.	0.9	236
32	Differential Sensitivity of Malignant Glioma Cells to Methylating and Chloroethylating Anticancer Drugs: p53 Determines the Switch by Regulating <i>xpc, ddb2</i> , and DNA Double-Strand Breaks. Cancer Research, 2007, 67, 11886-11895.	0.4	96
33	GENETIC ABERRATIONS IN GLIOMATOSIS CEREBRI. Neurosurgery, 2007, 60, 150-158.	0.6	32
34	Central Nervous System Tumors. Mayo Clinic Proceedings, 2007, 82, 1271-1286.	1.4	255
35	Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-Oncology, 2007, 9, 335-342.	0.6	71
36	Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opinion on Drug Delivery, 2007, 4, 175-186.	2.4	224

#	ARTICLE	IF	CITATIONS
37	Efficacy of Different Regimens of Adjuvant Radiochemotherapy for Treatment of Glioblastoma. <i>Tumori</i> , 2007, 93, 31-36.	0.6	11
38	High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 25, 1113-1119.	1.9	44
39	Treating high grade gliomas in the elderly: the end of ageism?. <i>Journal of Neuro-Oncology</i> , 2008, 86, 329-336.	1.4	22
40	A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2008, 88, 353-357.	1.4	51
41	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. <i>Cancer</i> , 2008, 112, 1337-1344.	2.0	44
42	Chemotherapy for glioblastoma. <i>Cancer</i> , 2008, 113, 2617-2622.	2.0	6
43	Antigen Retrieval for Proteomic Characterization of Formalin-Fixed and Paraffin-Embedded Tissues. <i>Journal of Proteome Research</i> , 2008, 7, 1098-1108.	1.8	70
44	Hypericin uptake: A prognostic marker for survival in high-grade glioma. <i>Journal of Clinical Neuroscience</i> , 2008, 15, 778-783.	0.8	12
45	Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat. <i>Vaccine</i> , 2008, 26, 1764-1772.	1.7	15
46	Surgery for high-grade gliomas in a developing country: survival estimation using a simple stratification system. <i>World Neurosurgery</i> , 2008, 70, 591-597.	1.3	10
47	Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma. <i>World Neurosurgery</i> , 2008, 70, S60-S63.	1.3	7
48	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology</i> , The, 2008, 9, 29-38.	5.1	487
49	Application of the Naïve Bayesian Classifier to optimize treatment decisions. <i>Radiotherapy and Oncology</i> , 2008, 86, 211-216.	0.3	65
51	Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3420-3428.	1.9	21
52	Temozolomide in Newly Diagnosed Malignant Gliomas: Administered Concomitantly with Radiotherapy, and Thereafter as Consolidation Treatment. <i>Onkologie</i> , 2008, 31, 309-313.	1.1	10
53	Applications of emerging molecular technologies in glioblastoma multiforme. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1497-1506.	1.4	22
54	PERSISTENT OUTPATIENT HYPERGLYCEMIA IS INDEPENDENTLY ASSOCIATED WITH DECREASED SURVIVAL AFTER PRIMARY RESECTION OF MALIGNANT BRAIN ASTROCYTOMAS. <i>Neurosurgery</i> , 2008, 63, 286-291.	0.6	110
55	Functional Magnetic Resonance Imaging-Guided Brain Tumor Resection. <i>Topics in Magnetic Resonance Imaging</i> , 2008, 19, 205-212.	0.7	19

#	ARTICLE	IF	CITATIONS
56	Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas. <i>Tumori</i> , 2008, 94, 674-680.	0.6	3
57	Perfusion MR imaging in adult neoplasia. , 0, , 341-368.		0
58	Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. <i>Journal of Neurosurgery</i> , 2009, 111, 282-292.	0.9	160
59	Prognostic Significance of Growth Kinetics in Newly Diagnosed Glioblastomas Revealed by Combining Serial Imaging with a Novel Biomathematical Model. <i>Cancer Research</i> , 2009, 69, 9133-9140.	0.4	206
60	Independent association of extent of resection with survival in patients with malignant brain astrocytoma. <i>Journal of Neurosurgery</i> , 2009, 110, 156-162.	0.9	696
61	Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 740-745.	0.8	1,413
62	Understanding the Origins of Gliomas and Developing Novel Therapies: Cerebrospinal Fluid and Subventricular Zone Interplay. <i>Seminars in Oncology</i> , 2009, 36, S17-S24.	0.8	18
63	Brain-skull contact boundary conditions in an inverse computational deformation model. <i>Medical Image Analysis</i> , 2009, 13, 659-672.	7.0	30
64	Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. <i>Journal of Neuro-Oncology</i> , 2009, 94, 79-85.	1.4	45
65	Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma?. <i>European Journal of Neurology</i> , 2009, 16, 874-878.	1.7	149
66	A treatment planning study on glioblastoma with different techniques using boron neutron capture therapy, 3-dimensional conformal radiotherapy, and intensity modulated radiotherapy. <i>Applied Radiation and Isotopes</i> , 2009, 67, 1180-1184.	0.7	1
67	Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastomas: Single-center experience. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 679-682.	0.6	38
68	Intérêt de l'association bÉvacizumab/irinotÉcan dans le traitement des glioblastomes. Une Étude multicentrique de l'ANOCEF. <i>Revue Neurologique</i> , 2009, 165, S16-S18.	0.6	0
69	Three-Tesla High-Field Applications. <i>Neurosurgery Clinics of North America</i> , 2009, 20, 173-178.	0.8	10
70	ASSOCIATION OF SURGICALLY ACQUIRED MOTOR AND LANGUAGE DEFICITS ON OVERALL SURVIVAL AFTER RESECTION OF GLIOBLASTOMA MULTIFORME. <i>Neurosurgery</i> , 2009, 65, 463-470.	0.6	355
71	Adipose-derived Stem Cells as Therapeutic Delivery Vehicles of an Oncolytic Virus for Glioblastoma. <i>Molecular Therapy</i> , 2010, 18, 377-385.	3.7	83
72	Neural networks and neuro-oncology: the complex interplay between brain tumour, epilepsy and cognition. , 0, , 149-184.		1
73	A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 2010, 112, 997-1004.	0.9	125

#	ARTICLE	IF	CITATIONS
74	Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. <i>Journal of Neurosurgery</i> , 2010, 112, 1020-1032.	0.9	39
75	Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. <i>Journal of Neurosurgery</i> , 2010, 113, 352-357.	0.9	117
76	HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 474-485.	3.2	324
77	Allyl isothiocyanate triggers G2/M phase arrest and apoptosis in human brain malignant glioma GBM 8401 cells through a mitochondria-dependent pathway. <i>Oncology Reports</i> , 2010, 24, 449-55.	1.2	43
78	The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth. <i>Clinical Cancer Research</i> , 2010, 16, 154-163.	3.2	197
79	Overexpression of c-erb B2 is a negative prognostic factor in anaplastic astrocytomas. <i>Diagnostic Pathology</i> , 2010, 5, 18.	0.9	23
80	The role of the PTEN gene in malignant gliomas. <i>Neurologia I Neurochirurgia Polska</i> , 2010, 44, 80-86.	0.6	24
81	Trends in survival of patients diagnosed with cancers of the brain and nervous system, thyroid, eye, bone, and soft tissues in the Nordic countries 1964–2003 followed up until the end of 2006. <i>Acta Oncologica</i> , 2010, 49, 673-693.	0.8	18
82	Multiple craniotomies in the management of multifocal and multicentric glioblastoma. <i>Journal of Neurosurgery</i> , 2011, 114, 576-584.	0.9	77
83	Glioblastoma cell lines derived under serum-free conditions can be used as an in vitro model system to evaluate therapeutic response. <i>Cancer Letters</i> , 2011, 305, 50-57.	3.2	8
84	Inactivation of ataxia telangiectasia mutated gene can increase intracellular reactive oxygen species levels and alter radiation-induced cell death pathways in human glioma cells. <i>International Journal of Radiation Biology</i> , 2011, 87, 432-442.	1.0	12
85	Surgical Treatment of Supratentorial Glioma in Eloquent Areas. , 0, , .		0
86	Neurosurgical Management of Gliomas. , 0, , .		0
87	Immunotherapy with Dendritic Cells and Newcastle Disease Virus in Glioblastoma Multiforme. , 0, , .		1
88	The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. <i>Neuropathology</i> , 2011, 31, 494-502.	0.7	71
89	Clinical significance of thallium-201 SPECT after postoperative radiotherapy in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2011, 103, 297-305.	1.4	3
90	Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. <i>Neurosurgical Review</i> , 2011, 34, 197-208.	1.2	15
91	Treatment of Glioblastoma in "Elderly" Patients. <i>Current Treatment Options in Oncology</i> , 2011, 12, 253-262.	1.3	33

#	ARTICLE	IF	CITATIONS
92	Radiotherapy Planning in High-grade Gliomas: a Survey of Current UK Practice. <i>Clinical Oncology</i> , 2011, 23, 189-198.	0.6	6
93	Cellular immunotherapy for high-grade glioma. <i>Immunotherapy</i> , 2011, 3, 423-434.	1.0	24
94	Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. <i>Journal of Neurosurgery</i> , 2011, 114, 604-612.	0.9	96
95	Achievement of Three Year Remission with Bevacizumab and Irinotecan in Recurrent Glioblastoma Multiforme: A case Report. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S6525.	0.6	5
96	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	0.6	105
97	Temozolomide plus radiotherapy for glioblastoma in a Canadian province: Efficacy versus effectiveness and the impact of O6-methylguanine-DNA-methyltransferase promoter methylation. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 229-238.	0.5	15
98	IL-13 receptor-directed cancer vaccines and immunotherapy. <i>Immunotherapy</i> , 2012, 4, 443-451.	1.0	14
99	Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma. <i>Journal of Immunotherapy</i> , 2012, 35, 159-168.	1.2	59
100	Phase I Clinical Trial Assessing Temozolomide and Tamoxifen With Concomitant Radiotherapy for Treatment of High-Grade Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 739-742.	0.4	34
101	Phase II Trial of Radiotherapy After Hyperbaric Oxygenation With Multiagent Chemotherapy (Procarbazine, Nimustine, and Vincristine) for High-Grade Gliomas: Long-Term Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 732-738.	0.4	25
102	Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 996-1000.	0.8	23
103	Subcellular tumor identification and markerless differentiation in the rat brain in vivo by multiphoton microscopy. <i>Lasers in Surgery and Medicine</i> , 2012, 44, 719-725.	1.1	8
104	Zerumbone suppresses IKK α , Akt, and FOXO1 activation, resulting in apoptosis of GBM 8401 cells. <i>Journal of Biomedical Science</i> , 2012, 19, 86.	2.6	41
105	Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. <i>Molecular Cancer</i> , 2012, 11, 32.	7.9	40
106	Estimation of Intraoperative Brain Deformation. <i>Studies in Mechanobiology, Tissue Engineering and Biomaterials</i> , 2012, , 97-133.	0.7	5
107	Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53. <i>Biomedicine and Pharmacotherapy</i> , 2012, 66, 433-438.	2.5	21
108	Anaplastic Gliomas. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 811-823.	0.9	7
109	Characteristics and Treatment of Seizures in Patients with High-Grade Glioma: A Review. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 227-235.	0.8	44

#	ARTICLE	IF	CITATIONS
110	Glioblastoma and malignant astrocytoma. , 2012, , 384-407.		3
111	A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature. PLoS ONE, 2012, 7, e41522.	1.1	82
112	Confocal Laser Endomicroscopy for Diagnosis and Histomorphologic Imaging of Brain Tumors In Vivo. PLoS ONE, 2012, 7, e41760.	1.1	85
113	Selection of DNA Aptamers against Glioblastoma Cells with High Affinity and Specificity. PLoS ONE, 2012, 7, e42731.	1.1	52
114	Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas. Journal of Oncology, 2012, 2012, 1-12.	0.6	12
115	Gross Total Resection of Glioma with the Intraoperative Fluorescence-guidance of Fluorescein Sodium. International Journal of Medical Sciences, 2012, 9, 708-714.	1.1	108
116	Introduction of Novel Semiquantitative Evaluation of 99mTc-MIBI SPECT Before and After Treatment of Glioma. Medicina (Lithuania), 2012, 48, 3.	0.8	2
117	Quantitative short echo time ¹ H MRSI of the peripheral edematous region of human brain tumors in the differentiation between glioblastoma, metastasis, and meningioma. Journal of Magnetic Resonance Imaging, 2012, 36, 1072-1082.	1.9	29
118	Glioblastoma. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 485-506.	1.0	18
119	Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery. Journal of Neuro-Oncology, 2012, 108, 327-332.	1.4	22
120	2011 Rita Schaffer Lecture: Nanoparticles for Intracellular Nucleic Acid Delivery. Annals of Biomedical Engineering, 2012, 40, 1408-1418.	1.3	14
121	Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathology and Applied Neurobiology, 2012, 38, 271-291.	1.8	97
122	Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. Journal of Neuro-Oncology, 2012, 106, 383-389.	1.4	68
123	Improved survival time trends for glioblastoma using the SEER 17 population-based registries. Journal of Neuro-Oncology, 2012, 107, 207-212.	1.4	332
124	Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. Journal of Cancer Research and Clinical Oncology, 2012, 138, 23-33.	1.2	14
125	Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Journal of Cancer Research and Clinical Oncology, 2013, 139, 829-835.	1.2	9
126	Denbinobin induces human glioblastoma multiforme cell apoptosis through the IKK α -Akt-FKHR signaling cascade. European Journal of Pharmacology, 2013, 698, 103-109.	1.7	11
127	Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. Journal of Clinical Neuroscience, 2013, 20, 818-823.	0.8	33

#	ARTICLE	IF	CITATIONS
128	Can the prognosis of individual patients with glioblastoma be predicted using an online calculator?. Neuro-Oncology, 2013, 15, 1074-1078.	0.6	15
129	Chemotherapy for gliomas in mainland China: An overview. Oncology Letters, 2013, 5, 1448-1452.	0.8	10
130	Impedance spectroscopyâ€”An outstanding method for label-free and real-time discrimination between brain and tumor tissue in vivo. Biosensors and Bioelectronics, 2013, 46, 8-14.	5.3	51
131	Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. Journal of Neurosurgery, 2013, 118, 786-798.	0.9	92
132	The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes and Development, 2013, 27, 985-990.	2.7	570
133	Pre-Operative Peritumoral Edema and Survival Rate in Glioblastoma Multiforme. Onkologie, 2013, 36, 9-9.	1.1	11
134	Multiple Microsurgical Resections for Repeated Recurrence of Glioblastoma Multiforme. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 261-268.	0.6	45
135	Extent of resection and radiotherapy in GBM: A 1973 to 2007 surveillance, epidemiology and end results analysis of 21,783 patients. International Journal of Oncology, 2013, 42, 929-934.	1.4	65
136	Challenges in clinical trial design for recurrent glioblastoma. Clinical Investigation, 2013, 3, 835-848.	0.0	3
137	Expression of the Arp2/3 complex in human gliomas and its role in the migration and invasion of glioma cells. Oncology Reports, 2013, 30, 2127-2136.	1.2	50
138	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. Brain Tumor Research and Treatment, 2013, 1, 2.	0.4	15
139	Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. OncoTargets and Therapy, 2013, 6, 1363.	1.0	127
140	Brain Tumor Stemness. , 2013, , .		0
141	The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. Cancers, 2014, 6, 1953-1985.	1.7	62
142	The need to continually redefine the goals of surgery for glioblastoma. Neuro-Oncology, 2014, 16, 611-612.	0.6	8
143	Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. Journal of Neurosurgery, 2014, 121, 1115-1123.	0.9	321
144	Stereovision to MR image registration for cortical surface displacement mapping to enhance imageâ€”guided neurosurgery. Medical Physics, 2014, 41, 102302.	1.6	18
145	Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes: a quantitative analysis of glioblastomas. Neuroradiology, 2014, 56, 1113-1120.	1.1	7

#	ARTICLE	IF	CITATIONS
146	The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. <i>British Journal of Neurosurgery</i> , 2014, 28, 438-446.	0.4	15
147	Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 291-301.	1.2	15
148	PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1 α suppression. <i>Journal of Neuro-Oncology</i> , 2014, 116, 89-97.	1.4	17
149	Rates and predictors of seizure freedom in resective epilepsy surgery: an update. <i>Neurosurgical Review</i> , 2014, 37, 389-405.	1.2	158
150	Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 113-122.	0.6	400
151	Impacts of MR spectroscopic imaging on glioma patient management. <i>Acta Oncologica</i> , 2014, 53, 580-589.	0.8	16
152	Management of High-Grade Gliomas in the Elderly. <i>Seminars in Radiation Oncology</i> , 2014, 24, 279-288.	1.0	16
153	Epigenetic regulation of the secreted frizzled-related protein family in human glioblastoma multiforme. <i>Cancer Gene Therapy</i> , 2014, 21, 297-303.	2.2	40
154	The role of imaging in the management of progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 118, 435-460.	1.4	144
155	The role of targeted therapies in the management of progressive glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 118, 557-599.	1.4	35
156	Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors. <i>Journal of Neuro-Oncology</i> , 2014, 119, 177-185.	1.4	35
157	When Gross Total Resection of a Glioblastoma Is Possible, How Much Resection Should Be Achieved?. <i>World Neurosurgery</i> , 2014, 82, e257-e265.	0.7	140
158	Osthole Inhibits Insulin-like Growth Factor-1-Induced Epithelial to Mesenchymal Transition via the Inhibition of PI3K/Akt Signaling Pathway in Human Brain Cancer Cells. <i>Journal of Agricultural and Food Chemistry</i> , 2014, 62, 5061-5071.	2.4	47
159	Glioblastoma Treatment in the Elderly in the Temozolomide Therapy Era. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 357-362.	0.3	5
160	Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy. <i>Oncology Letters</i> , 2015, 10, 379-383.	0.8	57
161	Identification of differentially expressed genes regulated by transcription factors in glioblastomas by bioinformatics analysis. <i>Molecular Medicine Reports</i> , 2015, 11, 2548-2554.	1.1	54
162	Intraoperative vascular DIVA surgery reveals angiogenic hotspots in tumor zones of malignant gliomas. <i>Scientific Reports</i> , 2015, 5, 7958.	1.6	29
163	A new functional classification system (FCA/B) with prognostic value for glioma patients. <i>Scientific Reports</i> , 2015, 5, 12373.	1.6	7

#	ARTICLE	IF	CITATIONS
164	Monitoring Tumor Targeting and Treatment Effects of IRDye 800CW and GX1-Conjugated Polylactic Acid Nanoparticles Encapsulating Endostar on Glioma by Optical Molecular Imaging. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00014.	0.7	7
165	EGFR and PTEN Gene Mutation Status in Glioblastoma Patients and their Prognostic Impact on Patient's Survival. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2015, 06, .	0.3	3
166	Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution. <i>Journal of Korean Medical Science</i> , 2015, 30, 1597.	1.1	8
167	International Differences in Treatment and Clinical Outcomes for High Grade Glioma. <i>PLoS ONE</i> , 2015, 10, e0129602.	1.1	11
168	Can Elderly Patients With Newly Diagnosed Glioblastoma be Enrolled in Radiochemotherapy Trials?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 23-27.	0.6	29
169	Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1131-1137.	1.2	30
170	High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma. <i>International Journal of Oncology</i> , 2015, 47, 1009-1016.	1.4	31
171	Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma. <i>Oncology Letters</i> , 2015, 10, 2769-2776.	0.8	49
172	Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 35-39.	0.8	30
173	Hypoxia Imaging in Gliomas With 18F-Fluoromisonidazole PET: Toward Clinical Translation. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 136-150.	2.5	60
174	The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2015, 121, 359-364.	1.4	102
175	Modulation of Sonic hedgehog signaling and WW domain containing oxidoreductase WOX1 expression enhances radiosensitivity of human glioblastoma cells. <i>Experimental Biology and Medicine</i> , 2015, 240, 392-399.	1.1	22
176	Intraoperative fiducial-less patient registration using volumetric 3D ultrasound: a prospective series of 32 neurosurgical cases. <i>Journal of Neurosurgery</i> , 2015, 123, 721-731.	0.9	11
177	Concepts of immunotherapy for glioma. <i>Journal of Neuro-Oncology</i> , 2015, 123, 323-330.	1.4	12
178	Increasing feasibility and utility of 18 F-FDOPA PET for the management of glioma. <i>Nuclear Medicine and Biology</i> , 2015, 42, 788-795.	0.3	42
179	PET, MRI, and simultaneous PET/MRI in the development of diagnostic and therapeutic strategies for glioma. <i>Drug Discovery Today</i> , 2015, 20, 306-317.	3.2	43
180	Peritumoral edema shown by MRI predicts poor clinical outcome in glioblastoma. <i>World Journal of Surgical Oncology</i> , 2015, 13, 97.	0.8	72
181	Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2015, 125, 307-315.	1.4	24

#	ARTICLE	IF	CITATIONS
182	PPIC, EMP3 and CHI3L1 Are Novel Prognostic Markers for High Grade Glioma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1808.	1.8	49
183	PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. <i>OncoTargets and Therapy</i> , 2016, 9, 3485.	1.0	48
184	COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. <i>Oncotarget</i> , 2016, 7, 70494-70503.	0.8	62
185	Immunological Evasion in Glioblastoma. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	41
186	Role of Redox Status in Development of Glioblastoma. <i>Frontiers in Immunology</i> , 2016, 7, 156.	2.2	108
187	Immunological Aspects of Malignant Gliomas. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 494-502.	0.3	13
188	Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study). <i>Chemotherapy</i> , 2016, 61, 269-274.	0.8	1
189	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	1.0	34
190	Long-term survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. <i>Radiology and Oncology</i> , 2016, 50, 394-401.	0.6	46
191	Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review. <i>Journal of Oncological Science</i> , 2016, 2, 87-94.	0.1	7
192	Radiomics in Brain Tumors. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2016, 24, 719-729.	0.6	73
193	Glioblastoma multiforme targeted therapy: The Chlorotoxin story. <i>Journal of Clinical Neuroscience</i> , 2016, 33, 52-58.	0.8	59
194	Intraoperative image updating for brain shift following dural opening. <i>Journal of Neurosurgery</i> , 2016, 126, 1924-1933.	0.9	27
195	Glioblastoma Multiforme (GBM) in the Elderly: Initial Treatment Strategy and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E87-E88.	0.4	1
196	Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. , 2016, 4, 28.		52
197	Upregulation of p72 enhances malignant migration and invasion of glioma cells by repressing Beclin1 expression. <i>Biochemistry (Moscow)</i> , 2016, 81, 574-582.	0.7	23
200	Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. <i>Pathology and Oncology Research</i> , 2016, 22, 633-637.	0.9	5
201	Effect of bexarotene on differentiation of glioblastoma multiforme compared with ATRA. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 417-429.	1.7	14

#	ARTICLE	IF	CITATIONS
202	Assessment of cytotoxic damage induced by irradiation combined with hyperthermia and Gemcitabine on cultured glioblastoma spheroid cells. <i>Radiation Physics and Chemistry</i> , 2016, 120, 44-48.	1.4	5
205	Glioblastoma multiforme (GBM) in the elderly: initial treatment strategy and overall survival. <i>Journal of Neuro-Oncology</i> , 2017, 134, 107-118.	1.4	25
206	Glioblastoma Multiforme: an Advanced Analysis of 153 Patients and Review of the Literature. <i>Brazilian Neurosurgery</i> , 2017, 36, 080-090.	0.0	2
207	Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. <i>NMR in Biomedicine</i> , 2017, 30, e3748.	1.6	23
208	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. <i>NeuroImage: Clinical</i> , 2017, 14, 87-96.	1.4	64
209	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	1.0	19
210	Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 135, 529-534.	1.4	20
211	Age groups related glioblastoma study based on radiomics approach. <i>Computer Assisted Surgery</i> , 2017, 22, 18-25.	0.6	3
212	New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. <i>Neuroradiology</i> , 2017, 59, 1223-1231.	1.1	12
213	Current Therapies and Future Directions in Treatment of Glioblastoma. <i>Current Cancer Research</i> , 2017, , 57-89.	0.2	1
214	Management of glioblastoma in elderly patients. <i>Journal of the Neurological Sciences</i> , 2017, 380, 250-255.	0.3	40
215	Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov. <i>Radiation Oncology</i> , 2017, 12, 1.	1.2	87
216	Volumetric Analysis Using Low-Field Intraoperative Magnetic Resonance Imaging for 168 Newly Diagnosed Supratentorial Glioblastomas: Effects of Extent of Resection and Residual Tumor Volume on Survival and Recurrence. <i>World Neurosurgery</i> , 2017, 98, 73-80.	0.7	44
217	Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea. <i>Cancer Research and Treatment</i> , 2017, 49, 193-203.	1.3	26
218	Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. <i>Metabolites</i> , 2017, 7, 20.	1.3	19
219	Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. <i>Pharmaceuticals</i> , 2017, 10, 24.	1.7	30
220	Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma. <i>Neurologia Medico-Chirurgica</i> , 2017, 57, 331-342.	1.0	36
221	General Considerations for Neurointerventional Procedures. , 2018, , 167-246.		1

#	ARTICLE	IF	CITATIONS
222	<scp>HOXC</scp>10 promotes proliferation and invasion and induces immunosuppressive gene expression in glioma. FEBS Journal, 2018, 285, 2278-2291.	2.2	35
223	Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. Journal of Neuro-Oncology, 2018, 139, 125-133.	1.4	26
224	Impact of a novel biomarker, Tâ€LAK cellâ€™originating protein kinase (TOPK) expression on outcome in malignant glioma. Neuropathology, 2018, 38, 144-153.	0.7	15
225	Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. World Neurosurgery, 2018, 116, e147-e161.	0.7	8
226	Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. Neurosurgery, 2018, 83, 76-85.	0.6	31
227	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. , 2018, 182, 70-79.		25
228	Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions. Investigative Magnetic Resonance Imaging, 2018, 22, 158.	0.2	5
229	Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nature Communications, 2018, 9, 4904.	5.8	62
230	Risk of Postoperative Performance Status Worsening after Resection of Lesions Involving the Motor Pathway: A Multinomial Logistic Regression Model. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2018, 79, 453-463.	0.4	12
231	Use of statins or NSAIDs and survival of patients with high-grade glioma. PLoS ONE, 2018, 13, e0207858.	1.1	22
232	Surgical Outcomes of Thalamic Tumors in Children: The Importance of Diffusion Tensor Imaging, Neuro-Navigation and Intraoperative Neurophysiological Monitoring. Brain Tumor Research and Treatment, 2018, 6, 60.	0.4	7
233	Impact of gender on the survival of patients with glioblastoma. Bioscience Reports, 2018, 38, .	1.1	88
234	Drug Repurposing of Metabolic Agents in Malignant Glioma. International Journal of Molecular Sciences, 2018, 19, 2768.	1.8	27
235	Extending the resection beyond the contrast-enhancement for glioblastoma: feasibility, efficacy, and outcomes. British Journal of Neurosurgery, 2018, 32, 528-535.	0.4	44
236	Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Letters, 2018, 433, 176-185.	3.2	28
237	Potential Anticancer Properties of Osthol: A Comprehensive Mechanistic Review. Nutrients, 2018, 10, 36.	1.7	70
238	Gold Nanoparticles for Brain Tumor Imaging: A Systematic Review. Frontiers in Neurology, 2018, 9, 328.	1.1	55
239	Glioblastoma single-cell microRaman analysis under stress treatments. Scientific Reports, 2018, 8, 7979.	1.6	3

#	ARTICLE	IF	CITATIONS
240	Which Parameter Is More Important for the Prognosis of New-Onset Adult Glioblastoma: Residual Tumor Volume or Extent of Resection?. <i>World Neurosurgery</i> , 2018, 116, e444-e451.	0.7	13
241	miR-204 reverses temozolomide resistance and inhibits cancer initiating cells phenotypes by degrading FAP- \pm in glioblastoma. <i>Oncology Letters</i> , 2018, 15, 7563-7570.	0.8	15
242	Use of metformin and survival of patients with high-grade glioma. <i>International Journal of Cancer</i> , 2019, 144, 273-280.	2.3	48
243	Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 663-677.	1.4	3
244	Improving survival prediction of high-grade glioma via machine learning techniques based on MRI radiomic, genetic and clinical risk factors. <i>European Journal of Radiology</i> , 2019, 120, 108609.	1.2	48
245	Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis. <i>World Neurosurgery</i> , 2019, 130, e236-e243.	0.7	6
246	Understanding the effect of vitamin B6 and PEG functionalization on improving the performance of carbon nanotubes in temozolomide anticancer drug transportation. <i>Journal Physics D: Applied Physics</i> , 2019, 52, 395402.	1.3	19
247	Downregulation of miR-485-3p promotes glioblastoma cell proliferation and migration via targeting RNF135. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 475-482.	0.8	22
248	Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics. <i>European Journal of Radiology</i> , 2019, 120, 108642.	1.2	23
249	Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma. <i>World Neurosurgery</i> , 2019, 126, e1510-e1517.	0.7	6
250	Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma. <i>Radiation Oncology</i> , 2019, 14, 73.	1.2	30
251	Extent of Resection for High- and Low-Grade Gliomas. , 2019, , 261-276.		0
252	Magnetic Particle Imaging in Neurosurgery. <i>World Neurosurgery</i> , 2019, 125, 261-270.	0.7	31
253	A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma. <i>Scientific Reports</i> , 2019, 9, 2615.	1.6	40
254	Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. <i>BMJ Case Reports</i> , 2019, 12, e228803.	0.2	4
255	Survival of glioma patients in relation to mobile phone use in Denmark, Finland and Sweden. <i>Journal of Neuro-Oncology</i> , 2019, 141, 139-149.	1.4	8
256	<sc>CA</sc>10 and <sc>CA</sc>11 negatively regulate neuronal activity-dependent growth of gliomas. <i>Molecular Oncology</i> , 2019, 13, 1018-1032.	2.1	12
257	Malignancy Index Using Intraoperative Flow Cytometry is a Valuable Prognostic Factor for Glioblastoma Treated With Radiotherapy and Concomitant Temozolomide. <i>Neurosurgery</i> , 2019, 84, 662-672.	0.6	20

#	ARTICLE	IF	CITATIONS
258	Lipid Fraction Derived From MRI In- and Opposed-Phase Sequence as a Novel Biomarker for Predicting Survival Outcome of Glioma. <i>Academic Radiology</i> , 2020, 27, 180-187.	1.3	3
259	Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images. <i>NMR in Biomedicine</i> , 2020, 33, e4229.	1.6	15
260	Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells. <i>Scientific Reports</i> , 2020, 10, 18238.	1.6	12
261	Ipilimumab: an investigational immunotherapy for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1187-1193.	1.9	16
262	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa093.	0.4	5
263	DeepSeg: deep neural network framework for automatic brain tumor segmentation using magnetic resonance FLAIR images. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 909-920.	1.7	134
264	Effects of supra-total resection in neurocognitive and oncological outcome of high-grade gliomas comparing asleep and awake surgery. <i>Journal of Neuro-Oncology</i> , 2020, 148, 97-108.	1.4	43
265	Glioblastoma and bevacizumab in elderly patients: Monocentric study. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 842-846.	0.5	6
266	Narrative review of palliative hypofractionated radiotherapy for high grade glioma. <i>Annals of Palliative Medicine</i> , 2021, 10, 846-862.	0.5	5
267	Trends and challenges in modeling glioma using 3D human brain organoids. <i>Cell Death and Differentiation</i> , 2021, 28, 15-23.	5.0	29
268	MGMT-Positive vs MGMT-Negative Patients With Glioblastoma: Identification of Prognostic Factors and Resection Threshold. <i>Neurosurgery</i> , 2021, 88, E323-E329.	0.6	13
269	Multiparametric MRI texture analysis in prediction of glioma biomarker status: added value of MR diffusion. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab051.	0.4	19
270	Brain Tumor Segmentation and Surveillance with Deep Artificial Neural Networks. , 2021, , 311-350.		6
271	Principles of Radiation Therapy for Glioblastoma Patients. <i>Molecular Pathology Library</i> , 2021, , 91-103.	0.1	0
272	Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 627650.	2.2	5
273	Cerrahi Tedavi Uygulanan Glioblastomlu Hastalarda Prognostik Faktörler ve Peritumoral Edem Sağ Kalım Özerine Etkisi. <i>Medical Journal of Western Black Sea</i> , 2021, 5, 226-231.	0.2	0
274	Extent of resection and survival in patients with glioblastoma multiforme. <i>Medicine (United States)</i> , 2021, 100, e26432.	0.4	21
275	Let Me See: Correlation between 5-ALA Fluorescence and Molecular Pathways in Glioblastoma: A Single Center Experience. <i>Brain Sciences</i> , 2021, 11, 795.	1.1	8

#	ARTICLE	IF	CITATIONS
276	neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival. <i>BMC Bioinformatics</i> , 2021, 22, 382.	1.2	3
277	FABP7 Facilitates Uptake of Docosahexaenoic Acid in Glioblastoma Neural Stem-like Cells. <i>Nutrients</i> , 2021, 13, 2664.	1.7	10
278	Highly Expressed CYBRD1 Associated with Glioma Recurrence Regulates the Immune Response of Glioma Cells to Interferon. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-12.	0.5	2
279	Anti-proliferative and apoptotic effects of green synthesized silver nanoparticles using <i>Lavandula angustifolia</i> on human glioblastoma cells. <i>3 Biotech</i> , 2021, 11, 374.	1.1	6
280	Impact of Immunohistochemical profiling of Glioblastoma multiforme on clinical outcomes: Real-world scenario in resource limited setting. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106726.	0.6	4
281	Palliative Care Consultation for Hospitalized Patients with Primary and Secondary Brain Tumors at a Single Academic Center. <i>Journal of Palliative Medicine</i> , 2021, 24, 1550-1554.	0.6	4
282	Prognostic factors and clinical nomogram predicting survival in high-grade glioma. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1052.	0.3	8
283	Tumor pO ₂ as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. <i>Advances in Experimental Medicine and Biology</i> , 2011, 701, 107-113.	0.8	8
284	Delineating Normal from Diseased Brain by Aminolevulinic Acid-Induced Fluorescence. , 2013, , 173-205.		3
285	Adult High-Grade (Diffuse) Glioma. <i>Molecular Pathology Library</i> , 2015, , 77-93.	0.1	2
286	Adult High-Grade Glioma. , 2007, , 59-69.		1
287	¹⁸ F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: a report of three cases. <i>Nuclear Medicine Communications</i> , 2010, 31, 482-487.	0.5	8
288	Interstitial imaging with multiple diffusive reflectance spectroscopy projections for in vivo blood vessels detection during brain needle biopsy procedures. <i>Neurophotonics</i> , 2019, 6, 1.	1.7	7
289	Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era. <i>PLoS ONE</i> , 2012, 7, e33684.	1.1	56
290	Improving the Extent of Malignant Glioma Resection by Dual Intraoperative Visualization Approach. <i>PLoS ONE</i> , 2012, 7, e44885.	1.1	97
291	The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 279-287.	0.6	9
292	Treatment Outcomes and Prognostic Factors in Adult Astrocytoma: In North East of Iran. <i>Iranian Journal of Cancer Prevention</i> , 2016, 9, e4099.	0.7	3
293	Clinicopathological analysis of HOXD4 expression in diffuse gliomas and its correlation with <i>IDH</i> mutations and 1p/19q co-deletion. <i>Oncotarget</i> , 2017, 8, 115657-115666.	0.8	9

#	ARTICLE	IF	CITATIONS
294	Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. <i>Oncotarget</i> , 2015, 6, 30968-30974.	0.8	38
295	3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. <i>Radiology and Oncology</i> , 2011, 45, 213-9.	0.6	4
296	Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?. <i>Frontiers in Neurology</i> , 2012, 3, 188.	1.1	17
297	miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. <i>International Journal of Molecular Medicine</i> , 2019, 43, 517-524.	1.8	29
298	The oncogenic roles of 27 α -hydroxycholesterol in glioblastoma. <i>Oncology Letters</i> , 2019, 18, 3623-3629.	0.8	9
299	Resting state functional connectivity magnetic resonance imaging integrated with intraoperative neuronavigation for functional mapping after aborted awake craniotomy. , 2016, 7, 13.		10
300	Socioeconomic status does not affect prognosis in patients with glioblastoma multiforme. , 2016, 7, 282.		25
301	Evaluation of rs1957106 Polymorphism of NF- κ B1 in Glioblastoma Multiforme in Isfahan, Iran. <i>Advanced Biomedical Research</i> , 2019, 8, 9.	0.2	3
302	Significant effect of anti-tyrosine kinase inhibitor (Gefitinib) on overall survival of the glioblastoma multiforme patients in the backdrop of mutational status of epidermal growth factor receptor and PTEN Genes. <i>Journal of Innovative Optical Health Sciences</i> , 2018, 13, 46.	0.5	8
303	Efficacy of clinical prognostic factors on survival in patients with glioblastoma. <i>Turkish Neurosurgery</i> , 2009, 20, 117-25.	0.1	20
304	Combined Multi-portal α -Pull-Through α -Keyhole Craniotomy. , 2021, , 187-195.		0
305	Combined Keyhole Craniotomies for Multifocal or Multiple Lesions. , 2021, , 196-202.		0
306	Transcochlear and Extended/Combined Transcochlear Approaches for Complex Tumors of the Skull Base and Posterior Cranial Fossa. , 2021, , 122-139.		0
307	Combined Middle Fossa Craniotomy and Mastoidectomy for Cerebrospinal Fluid Leak Repair and Encephalocele Resection. , 2021, , 111-121.		0
308	Combined Suboccipital Craniotomy and Neck Dissection. , 2021, , 158-163.		0
309	Transbasal and Transfacial Approach for Paranasal and Anterior Cranial Fossa Tumors. , 2021, , 104-110.		0
310	Combined Retrosigmoid and Orbitozygomatic Approach. , 2021, , 140-149.		0
311	Combined Petrosal Approach. , 2021, , 164-181.		0

#	ARTICLE	IF	CITATIONS
312	Combined Retrosigmoid and Limited Anterior Petrosectomy (â€œReverse Petrosectomyâ€). , 2021, , 150-157.		0
313	Combined Orbitofrontal Craniotomy and Direct Orbital Decompression. , 2021, , 95-103.		0
314	Combined Endoscopic Endonasal and Transcranial Approach to Complex Intracranial Lesions. , 2021, , 35-50.		0
316	Combined Endoscopic Endonasal and Transcervical Approach. , 2021, , 29-34.		0
317	Combined Endonasal Transthemoidal, Transcribriform, and Endoscope-Assisted Supraorbital Craniotomy. , 2021, , 1-8.		0
318	Combined Transsylvian-Subtemporal Approach to Anterior Circulation and Basilar Apex Aneurysms. , 2021, , 214-222.		0
321	Combined Keyhole Paramedian Supracerebellar-Transtentorial Approach. , 2021, , 182-186.		0
322	Combined Endonasal and Transorbital Approach. , 2021, , 9-24.		0
323	Combined Transcranial Approach for Tumor Resection and Anterior Circulation Vascular Bypass. , 2021, , 51-66.		0
324	Hybrid/Combined Strategies for Vestibular Schwannomas. , 2021, , 67-78.		0
325	Transchoroidal, Subchoroidal, and Combined Approaches to the Third Ventricle. , 2021, , 79-94.		0
326	Combined Endonasal and Transoral Endoscopic Approach to the Craniovertebral Junction. , 2021, , 25-28.		0
327	Combined Microsurgical and Endovascular Treatment of Cerebrovascular and Skull Base Pathology. , 2021, , 203-213.		0
329	Pineal Region Tumors: Chemotherapy Perspective. , 2008, , 377-382.		0
330	Functional Magnetic Resonance-Guided Brain Tumor Resection. , 2010, , 107-120.		1
331	Treatment options and effects of survival in glioblastoma multiforme. The Journal of Kartal Training and Research Hospital, 2012, 23, 25-29.	0.0	0
332	Progenitores de los tumores cerebrales.. Revista Colombiana De Hematologïa Y Oncologïa, 2012, 1, 36-50.	0.0	0
333	Functional Magnetic Resonance-Guided Brain Tumor Resection. , 2013, , 155-168.		0

#	ARTICLE	IF	CITATIONS
334	Malignant Tumors of the Central Nervous System. , 2014, , 481-495.		0
335	Awake Craniotomies: Burden or Benefit for the Patient?. , 2015, , 949-962.		0
336	Glioblastoma multiforme (GBM). , 2015, , 225-236.		0
337	Modulated radiotherapy with concurrent and adjuvant temozolomide for anaplastic gliomas: Indian single-center data. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 495.	0.1	0
338	Cancer Rehabilitation in Geriatric Patients. Handbooks in Health, Work, and Disability, 2018, , 207-228.	0.0	0
339	Evaluation of rs1982073 polymorphism of transforming growth factor- β 1 in glioblastoma. Journal of Research in Medical Sciences, 2019, 24, 40.	0.4	1
340	Diagnosis, treatment, and survival in spinal dissemination of primary intracranial glioblastoma: systematic literature review. Journal of Neurosurgery: Spine, 2019, 31, 723-732.	0.9	11
341	Malignant Tumors of the Central Nervous System. , 2020, , 507-524.		0
342	GBM Olgularında Adjuvan Radyoterapi Sonrasında Nörolojik Paterninin Doz Dağılımı ile İlişkisi: EORTC ve RTOG Kuvavuzları'nın Değerlendirilmesi. Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 0, ,	0.0	0
343	Brain Tumor Detection in MRI Images Using Image Processing Techniques. , 2021, , .		6
344	A review of management strategies of malignant gliomas in the elderly population. American Journal of Cancer Research, 2014, 4, 436-44.	1.4	9
345	Red blood cell distribution width in glioblastoma. Clinical Neurology and Neurosurgery, 2022, 213, 107096.	0.6	0
346	Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma. Frontiers in Neuroscience, 2021, 15, 791776.	1.4	6
347	How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme. Pharmacological Reports, 2022, 74, 323-339.	1.5	6
348	Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for resection of high-grade gliomas: A systematic review and network meta-analysis. Journal of Clinical Neuroscience, 2022, 98, 240-247.	0.8	14
349	The role of the default mode network in longitudinal functional brain reorganization of brain gliomas. Brain Structure and Function, 2022, 227, 2923-2937.	1.2	9
350	Advanced MR (MR Spectroscopy, Diffusion Imaging, Diffusion Tensor Imaging, and Perfusion Imaging). , 2011, , 79-125.		0
352	Bisdemethoxycurcumin suppresses human brain glioblastoma multiforme (GBM) cell migration and invasion via affecting NF- κ B and MMP-2 and MMP-9 signaling pathway in vitro. Environmental Toxicology, 2022, 37, 2388-2397.	2.1	9

#	ARTICLE	IF	CITATIONS
353	The Impact of Extent of Resection on the Prognosis of Glioblastoma Multiforme: A Systematic Review and Meta-analysis. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 345-354.	0.1	0
354	Evaluation of the glioblastoma multiforme treatment with hyperthermia using the finite element method. Numerical Heat Transfer; Part A: Applications, 0, , 1-22.	1.2	2
355	Recurrent glioblastoma in elderly: Options and decision for the treatment. , 0, 13, 397.		6
356	Inhibition of human glioblastoma multiforme cells by 10,11-dehydrocurvularin through the MMP-2 and PI3K/AKT signaling pathways. European Journal of Pharmacology, 2022, 936, 175348.	1.7	1
357	An intelligent brain tumor segmentation using improved Deep Learning Model Based on Cascade Regression method. Multimedia Tools and Applications, 2023, 82, 20059-20078.	2.6	4
358	The Role of Surgery in High-grade Glioma " Is Surgical Resection Justified? A Review of the Current Knowledge. Annals of the Academy of Medicine, Singapore, 2007, 36, 358-363.	0.2	34
359	Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity. Yonsei Medical Journal, 2023, 64, 139.	0.9	2
360	A rare, giant, anaplastic oligodendroglioma. Radiology Case Reports, 2023, 18, 1544-1548.	0.2	0
361	Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier. Frontiers in Immunology, 0, 14, .	2.2	4
362	Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI. Cancers, 2023, 15, 1440.	1.7	1
363	The Current State of Adult Glial Tumor Patients' Care in Kazakhstan: Challenges in Diagnosis and Patterns in Survival Outcomes. Biomedicines, 2023, 11, 886.	1.4	2
364	Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review. Journal of Neuro-Oncology, 2023, 162, 267-293.	1.4	5
365	A Comparative Analysis on Predicting Brain Tumor from MRI FLAIR Images Using Deep Learning. , 2023, , .		0
369	General Considerations for Neurointerventional Procedures. Contemporary Medical Imaging, 2023, , 173-262.	0.3	0